A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response
연구 개요
상세 설명
During a pre-study run-in phase patients with chronic hepatitis C genotype 2/3, who had started therapy with PEG-IFN alfa-2a plus ribavirin according to local standard of care and did not achieve a rapid viral response (RVR) (defined as Hepatitis C virus (HCV) RNA <15 IU/mL at Week 4 of treatment measured with the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test) were eligible for the study and entered the screening phase between treatment Week 4 and 8 as soon as the result of the Week 4 HCV RNA test was available.
Eligible patients entered the study and continued with the dose regimens of PEG-IFN alfa-2a and ribavirin they were taking prior to enrolment into the trial up to Week 24 of treatment. Patients who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24, were randomized at treatment Week 24 to one of the two study groups. Upon randomization, participants either stopped treatment (equaling 24 weeks of treatment) or continued treatment for another 24 weeks (equaling 48 weeks of treatment). A treatment free follow-up period of 24 weeks (for participants in the 48-week treatment group) or 48 weeks (participants in the 24-week treatment group) completed the study.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일, 13353
-
Berlin, 독일, 10969
-
Bonn, 독일, 53127
-
Düsseldorf, 독일, 40225
-
Düsseldorf, 독일, 40237
-
Frankfurt Am Main, 독일, 60590
-
Freiburg, 독일, 79106
-
Giessen, 독일, 35392
-
Hamburg, 독일, 20099
-
Heidelberg, 독일, 69120
-
Jena, 독일, 07747
-
Kiel, 독일, 24105
-
Köln, 독일, 50937
-
Mainz, 독일, 55101
-
München, 독일, 81675
-
Offenburg, 독일, 77654
-
Tübingen, 독일, 72076
-
ULM, 독일, 89081
-
-
-
-
-
Guadalajara, 멕시코, 44160
-
Guadalajara, 멕시코, 44670
-
Mexicali, 멕시코, 21000
-
Mexico City, 멕시코, 14050
-
Mexico Df, 멕시코, 11649
-
Puebla, 멕시코, 72560
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
-
-
California
-
La Jolla, California, 미국, 92037-1030
-
Lancaster, California, 미국, 93534
-
Long Beach, California, 미국, 90822
-
Los Angeles, California, 미국, 90048
-
Los Angeles, California, 미국, 90057
-
Sacramento, California, 미국, 95817
-
Sacramento, California, 미국, 95816
-
San Diego, California, 미국, 92103-8465
-
Torrance, California, 미국, 90505
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
-
-
Florida
-
Jacksonville, Florida, 미국, 32256
-
Orlando, Florida, 미국, 32803
-
-
Georgia
-
Atlanta, Georgia, 미국, 30308
-
Marietta, Georgia, 미국, 30060
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70890
-
Opelousas, Louisiana, 미국, 70520
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
-
-
Mississippi
-
Tupelo, Mississippi, 미국, 38801
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
-
St Louis, Missouri, 미국, 63104
-
-
New Jersey
-
Egg Harbour Township, New Jersey, 미국, 08234
-
Hackensack, New Jersey, 미국, 07601
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
-
-
New York
-
New York, New York, 미국, 10016
-
Syracuse, New York, 미국, 13210
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28801
-
Chapel Hill, North Carolina, 미국, 27599-7080
-
Winston-salem, North Carolina, 미국, 27103
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73112-4481
-
-
Oregon
-
Portland, Oregon, 미국, 97239
-
-
Tennessee
-
Kingsport, Tennessee, 미국, 37660
-
-
Texas
-
Fort Sam Houston, Texas, 미국, 78234-3879
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
-
Fairfax, Virginia, 미국, 22031
-
Richmond, Virginia, 미국, 23249
-
-
-
-
-
Antwerpen, 벨기에, 2650
-
Bruxelles, 벨기에, 1020
-
Bruxelles, 벨기에, 1070
-
Bruxelles, 벨기에, 1000
-
Gent, 벨기에, 9000
-
Kortrijk, 벨기에, 8500
-
Liege, 벨기에, 4000
-
-
-
-
-
Brasilia, 브라질, 70335-000
-
Campinas, 브라질, 13081-970
-
Campinas, 브라질, 13012-970
-
Porto Alegre, 브라질, 90020-090
-
Porto Alegre, 브라질, 90035-003
-
Ribeirao Preto, 브라질, 14049-900
-
Rio de Janeiro, 브라질, 20020-022
-
Santo Andre, 브라질, 09060-650
-
Sao Luis, 브라질, 78048-790
-
Sao Paulo, 브라질, 04040-003
-
Sorocaba, 브라질, 18047-600
-
Vitoria, 브라질, 29043-260
-
-
-
-
-
Lausanne, 스위스, 1005
-
Lugano, 스위스, 6903
-
St. Gallen, 스위스, 9007
-
Zürich, 스위스, 8091
-
-
-
-
-
Graz, 오스트리아, 8036
-
Innsbruck, 오스트리아, 6020
-
Linz, 오스트리아, 4010
-
Oberndorf, 오스트리아, 5110
-
Wien, 오스트리아, 1160
-
Wien, 오스트리아, 1090
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 2B7
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z 2K5
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8N 4A6
-
Mississauga, Ontario, 캐나다, L5M 4N4
-
-
-
-
-
Santurce, 푸에르토 리코, 00909
-
-
-
-
-
Darlinghurst, 호주, 2010
-
Fremantle, 호주, 6160
-
Melbourne, 호주, 3186
-
Nedlands, 호주, 6009
-
Sydney, 호주, 2139
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- adult patients, >=18 years of age;
- serological evidence of chronic hepatitis C (CHC);
- CHC genotype 2 or 3;
- receiving PEGASYS + Copegus according to local standard of care and no rapid viral response (RVR);
- compensated liver disease.
Exclusion Criteria:
- pegylated interferon, standard interferon or ribavirin therapy at any time prior to initiation of current therapy with PEGASYS + Copegus;
- coinfection with hepatitis A or B, or human immunodeficiency virus (HIV);
- history or other evidence of decompensated liver disease.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: PEG-IFN alfa-2a + Ribavirin for 24 weeks
After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped.
Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
|
다른 이름들:
다른 이름들:
|
|
활성 비교기: PEG-IFN alfa-2a + Ribavirin for 48 weeks
After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment).
Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
|
다른 이름들:
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment
기간: 24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.
|
Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) 24 weeks after scheduled treatment completion, defined as Week 44 or later for participants randomized to the 24-week treatment period or Week 68 or later for participants randomized to the 48-week treatment period. Participants without measurements at the end of the 24-week untreated follow-up period were considered non-responders in the analysis. |
24 weeks after scheduled treatment completion (approximately Week 48 for participants in the 24-week treatment group and Week 72 for participants in the 48-week treatment group.
|
|
Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment
기간: 24 weeks after actual end of treatment (range from Week 48 to Week 72).
|
Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 24 weeks after actual end of study treatment.
For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 24 weeks after actual end of treatment were used in the analysis.
Participants without a 24-week post treatment measurement are considered non-responders.
|
24 weeks after actual end of treatment (range from Week 48 to Week 72).
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation
기간: Week 72
|
Virological response 72 weeks after treatment initiation is defined as the percentage of participants with HCV RNA <15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test at 48 weeks post completion of the 24 week treatment period and 24 weeks post completion of the 48 week treatment period. Participants without Week 72 measurements were considered non-responders in the analysis. |
Week 72
|
|
Percentage of Participants With Virological Response at End of Treatment
기간: End of Treatment (Week 24 and Week 48 for each treatment group respectively).
|
Virological response at the end of treatment was defined as the percentage of participants with HCV RNA <15 IU/mL as measured by the Roche COBAS AmpliPrep / COBAS TaqMan® HCV Test after the last dose of study medication.
|
End of Treatment (Week 24 and Week 48 for each treatment group respectively).
|
|
Percentage of Participants With Virological Relapse
기간: End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).
|
Virological relapse defined as the percentage of participants with a virological response at end of treatment but who did not have a sustained virological response 24 weeks after the end of treatment. Virological response at end of treatment is defined as a single last HCV RNA measurement <15 IU/ml measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test at the day of last dose of study medication. Sustained virological response 24 weeks after the actual treatment end (SVR24) is defined as a single last HCV RNA measurement <15 IU/ml at least 20 weeks after treatment end. |
End of treatment (Weeks 24 or 48) and 24 weeks after the end of treatment (weeks 48 and 72 in each treatment group respectively).
|
|
Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment
기간: 12 weeks after actual end of treatment (range from Week 36 to Week 60)
|
Sustained virological response (SVR) is defined as a single last HCV RNA measurement <15 IU/ml (measured using the Roche COBAS AmpliPrep / COBAS TaqMan HCV Test) at 12 weeks after actual end of study treatment.
For participants in the 48-week treatment group who stopped study treatment prior to Week 48 for any reason, the HCV RNA measurements 12 weeks after actual end of treatment were used in the analysis.
Participants without a 12-week post treatment measurement are considered non-responders.
|
12 weeks after actual end of treatment (range from Week 36 to Week 60)
|
|
Number of Participants With Adverse Events (AEs)
기간: From Week 1 through Week 72.
|
An AE was defined as a sign or symptom, including intercurrent illness, that occurred during the course of the clinical study after treatment had started.
A related AE is an event assessed by the Investigator to be remotely, possibly, or probably related to study treatment according to criteria provided in the protocol.
A severe AE was an event graded by the Investigator as "incapacitating with inability to work or perform normal daily activity".
A serious AE (SAE) was defined as any experience that suggests a significant hazard, contraindication, side effect or precaution.
This includes any experience which was fatal; was life-threatening; required inpatient hospitalization or prolongation of an existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/ birth defect; was medically significant or required intervention to prevent one or other of the outcomes listed above.
|
From Week 1 through Week 72.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- MV21371
- 2007-004993-15
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .